Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0109 | 0.7576 | 1 |
Mycobacterium tuberculosis | Probable reductase | 0.0098 | 0.6632 | 0.8342 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0098 | 0.6632 | 0.8342 |
Brugia malayi | glutathione reductase | 0.0043 | 0.1881 | 0.5 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0109 | 0.7576 | 1 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0098 | 0.6632 | 0.8342 |
Toxoplasma gondii | sortilin, putative | 0.0073 | 0.4438 | 1 |
Plasmodium falciparum | sortilin | 0.0073 | 0.4438 | 1 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0098 | 0.6632 | 0.8342 |
Leishmania major | trypanothione reductase | 0.0043 | 0.1881 | 0.5 |
Schistosoma mansoni | sortilin | 0.0052 | 0.261 | 0.261 |
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0098 | 0.6632 | 0.8342 |
Trypanosoma brucei | trypanothione reductase | 0.0043 | 0.1881 | 0.5 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0098 | 0.6632 | 0.8342 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0043 | 0.1881 | 0.5 |
Brugia malayi | Thioredoxin reductase | 0.0043 | 0.1881 | 0.5 |
Echinococcus multilocularis | sortilin | 0.0073 | 0.4438 | 1 |
Plasmodium vivax | sortilin, putative | 0.0073 | 0.4438 | 1 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0109 | 0.7576 | 1 |
Echinococcus granulosus | sortilin | 0.0073 | 0.4438 | 1 |
Loa Loa (eye worm) | glutathione reductase | 0.0043 | 0.1881 | 0.5 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0043 | 0.1881 | 0.5 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0109 | 0.7576 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.